NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
Clinical Trials
13 trialsNCT05819892 2026-03-11
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06830239 2026-02-12
Superhero
Universitaire Ziekenhuizen KU Leuven
Phase 2 Recruiting
NCT07408063 2026-02-12
BeeHive
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT04068753 2026-02-10
STAR
University of Oklahoma
Phase 2 Active not recruiting
NCT05700721 2026-02-05
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04774419 2026-02-03
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07381777 2026-02-02
IMMUNOSTAR
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Not yet recruiting
NCT04165772 2026-01-23
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07336147 2026-01-14
Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma
Chang Gung Memorial Hospital
Phase 2 Recruiting
NCT06238635 2026-01-13
Dostarlimab and Cobolimab in Advanced Cervical Cancer
Beth Israel Deaconess Medical Center
Phase 2 Active not recruiting
NCT04673448 2026-01-09
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
Phase 1 Active not recruiting
NCT03955978 2026-01-06
TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
Washington University School of Medicine
Phase 1 Active not recruiting